Floatz logo

Therapeutic Asset Ratings

200 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Tislelizumab
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP2CCC (53)
Tislelizumab
CART Therapy
Ruijin HospitalP2CCC (53)
Tislelizumab
CNS Lymphoma
Ruijin HospitalP2CCC (53)
Toripalimab
Chemoradiotherapy
Ruijin HospitalP2CCC (53)
Toripalimab
Rectal Cancer Patients
Ruijin HospitalP2CCC (53)
Toripalimab
Targeted Therapy
Ruijin HospitalP2CCC (53)
Toripalimab
Total Neoadjuvant Therapy
Ruijin HospitalP2CCC (53)
Toripalimab
Total Neoadjuvant Treatment
Ruijin HospitalP2CCC (53)
Tucidinostat
Double-expressor Lymphoma
Ruijin HospitalP2CCC (53)
Tucidinostat
THL
Ruijin HospitalP2CCC (53)
Vah
Leukemia
Ruijin HospitalP2CCC (53)
Vesanoid
Mantle Cell Lymphoma (MCL)
Ruijin HospitalP2CCC (53)
VINCRISTINE SULFATE
CART Therapy
Ruijin HospitalP2CCC (53)
Zanubrutinib
CART Therapy
Ruijin HospitalP2CCC (53)
Avastinib
Acute Myeloid Leukemia
Ruijin HospitalP2/3CCC (52)
Apg-2575
Large B-cell Lymphoma
Ruijin HospitalP2CCC (51)
Midodrine
Ischemic Stroke
Ruijin HospitalP2CCC (51)
Penpulimab
Rectal Carcinoma
Ruijin HospitalP2CCC (51)
Tislelizumab
Large B-Cell Lymphoma
Ruijin HospitalP2CCC (51)
Tofacitinib
Diffuse Large B-Cell Lymphoma
Ruijin HospitalP2CCC (51)
Toripalimab
Rectal Carcinoma
Ruijin HospitalP2CCC (51)
Vesanoid
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP2CCC (51)
Hrs-4642
Pancreatic Neoplasm
Ruijin HospitalP2CCC (50)
Sonrotoclax
Acute Myeloid Leukemia
Ruijin HospitalP2CCC (50)
BMS-986345
Richter Syndrome
Ruijin HospitalP1/2CCC (49)
Showing 101 to 125 of 200 assets
PreviousPage 5 of 8Next